Patients were then re-randomized to either pen or vial-and-syringe for further observation ( @ , @ , and @ weeks ) to evaluate clinical end points ( glycosylated hemoglobin -LSB- A@C -RSB- and fasting blood glucose levels ) and safety outcomes ( hypoglycemia and adverse events ) .